3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter.

The fermenter adds to 3P's capacity for manufacturing biological medicinal products using microbial technology.

3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological products complements its existing capacity for protein production from bacteria and yeast through installation of a new 500-litre stainless steel fermenter with fermentation technology.

The addition of this new capacity complements the existing three fermentation lines that carry out drug production from bacteria and yeast. This means that 3P Biopharmaceuticals now has availability of 10 L, 100L, 500L and 1,000 L capacities for microbial manufacturing.

The new fermenter that fully complies with the regulatory standards of Good Manufacturing Practices (GMPs) of the European Medicines Agency (EMA), will allow the Navarran biotech company to multiply by five the production capacity of one of its three microbial manufacturing lines.

Dámaso Molero, CEO of 3P Biopharmaceuticals is very positive and states that “the demand for microbial protein manufacturing capacity is increasing nowadays and customers require more capacity for their projects. At 3P we will always be ready to adapt to meet all of their needs”.

Elena Erroba, Business Development Director at 3P explains: “3P has a proven and established reputation as a leading CDMO in the manufacture of biologic medicines with microbial technology and the expansion of our capacity with this new 500 L fermenter allows us to support new and existing customers in the clinical development and commercial supply of their therapies”.

With the recent renovations that 3P has carried out over the last three years, its facilities now total 10,500 m2. The main purpose of the remodelling is to further expand its production capacity and increase the efficiency of its process development and manufacturing services.

In 2022, 3P Biopharmaceuticals celebrated its 15th anniversary and closed the year with a turnover of more than 42 million euros and a 22% growth. 3P now has more than 350 employees and is currently collaborating with more than 25 international clients, consolidating ongoing projects, and initiating new ones.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.